DEBx Medical ’s Post

Outcome-Driven Wound Care: A Review of the Latest Clinical Evidence Looking at the Reliability and Transferability of RCT Data to the Real-World Impact on Patients November 19, 2024, at 12 PM EST In this upcoming webinar, Dr. Windy Cole, DPM, CWSP, will review RCT data for Affinity, the only fresh, placental allograft with living cells shown to support improved time-to-wound closure, examine new real-world data supporting the use of Affinity in hard-to-heal diabetic foot ulcers (DFUs), and discuss how this data translates to real-world clinical practice and outcomes featuring case studies. Register today: https://okt.to/YaV0zp Sponsored by Organogenesis

Outcome-Driven Wound Care: A Review of the Latest Clinical Evidence Looking at the Reliability and Transferability of RCT Data to the Real-World Impact on Patients November 19, 2024, at 12 PM EST In this upcoming webinar, Dr. Windy Cole, DPM, CWSP, will review RCT data for Affinity, the only fresh, placental allograft with living cells shown to support improved time-to-wound closure, examine new real-world data supporting the use of Affinity in hard-to-heal diabetic foot ulcers (DFUs), and discuss how this data translates to real-world clinical practice and outcomes featuring case studies. Register today: https://okt.to/RBqo4m Sponsored by Organogenesis

Outcome-Driven Wound Care: A Review of the Latest Clinical Evidence Looking at the Reliability and Transferability of RCT Data to the Real-World Impact on Patients November 19, 2024, at 12 PM EST In this upcoming webinar, Dr. Windy Cole, DPM, CWSP, will review RCT data for Affinity, the only fresh, placental allograft with living cells shown to support improved time-to-wound closure, examine new real-world data supporting the use of Affinity in hard-to-heal diabetic foot ulcers (DFUs), and discuss how this data translates to real-world clinical practice and outcomes featuring case studies. Register today: https://okt.to/m5ugrz Sponsored by Organogenesis

Outcome-Driven Wound Care: A Review of the Latest Clinical Evidence Looking at the Reliability and Transferability of RCT Data to the Real-World Impact on Patients November 19, 2024, at 12 PM EST In this upcoming webinar, Dr. Windy Cole, DPM, CWSP, will review RCT data for Affinity, the only fresh, placental allograft with living cells shown to support improved time-to-wound closure, examine new real-world data supporting the use of Affinity in hard-to-heal diabetic foot ulcers (DFUs), and discuss how this data translates to real-world clinical practice and outcomes featuring case studies. Register today: https://okt.to/grv1Kt Sponsored by Organogenesis

Outcome-Driven Wound Care: A Review of the Latest Clinical Evidence Looking at the Reliability and Transferability of RCT Data to the Real-World Impact on Patients November 19, 2024, at 12 PM EST In this upcoming webinar, Dr. Windy Cole, DPM, CWSP, will review RCT data for Affinity, the only fresh, placental allograft with living cells shown to support improved time-to-wound closure, examine new real-world data supporting the use of Affinity in hard-to-heal diabetic foot ulcers (DFUs), and discuss how this data translates to real-world clinical practice and outcomes featuring case studies. Register today: https://okt.to/MRSngL Sponsored by Organogenesis

With Ochsner Digital Medicine, managing cardiometabolic conditions has gotten smarter. Our program leverages an algorithmic approach that transforms complex medical insights into actionable solutions. This method ensures that evidence-based care is delivered consistently across populations—achieving excellent high blood pressure and Type 2 diabetes control rates. According to Kenny Cole, MD, MS, the medical director for Digital Medicine, this advanced patient care reduces the risk of even more costly complications. “When you're achieving hypertension or diabetes control rates of greater than 90%,” Says Dr. Cole, “you are then reducing the risk of things like heart attack or strokes, or progression of chronic kidney disease. “These are conditions that become much more expensive to manage once they have more fully evolved and complications have ensued." Watch this short video to learn more about Digital Medicine’s breakthrough approach. And if your organization is looking to add a proven, data-driven cardiometabolic care solution to your offerings, this is the moment to partner with a leader in innovation and results.

Outcome-Driven Wound Care: A Review of the Latest Clinical Evidence Looking at the Reliability and Transferability of RCT Data to the Real-World Impact on Patients November 19, 2024, at 12 PM EST In this upcoming webinar, Dr. Windy Cole, DPM, CWSP, will review RCT data for Affinity, the only fresh, placental allograft with living cells shown to support improved time-to-wound closure, examine new real-world data supporting the use of Affinity in hard-to-heal diabetic foot ulcers (DFUs), and discuss how this data translates to real-world clinical practice and outcomes featuring case studies. Register today: https://okt.to/5bfnzI Sponsored by Organogenesis

"𝗦𝗰𝗹𝗲𝗿𝗼𝗦𝗮𝗳𝗲™ is ideal for treating complex venous systems surrounding Ulcer beds. Its unique Dual Injection and Aspiration mechanism ensures precise targeting of the treatment area while minimizing the inflammatory response", says Dr. Avrahami, a leading expert in vascular medicine, at the TLM Medical Center in Tel-Aviv. Innovative advancements in the treatment of varicose veins continue to make a significant impact on treatment results and patient satisfaction, thanks to the pioneering work of Dr. Ram Avrahami, He has extensively researched 𝗦𝗰𝗹𝗲𝗿𝗼𝗦𝗮𝗳𝗲™, a non-thermal, non-tumescent technique for endovenous treatment. His studies show it effectively treats venous ulcers and C5 disease with minimal discomfort and downtime, promoting faster healing and better patient outcomes. Additionally, combining 𝗦𝗰𝗹𝗲𝗿𝗼𝗦𝗮𝗳𝗲™ with biological autologous varicose vein dressings significantly enhances healing compared to traditional dressings, offering a superior solution for endovenous ablation patients. Schedule a demo: https://lnkd.in/dEE7ZW9R (links in the first comment) #venousulcer #varicoseveins

We are excited to share the publication of a pivotal new article in Journal of Thrombosis and Haemostasis (JTH) Safe and Effective Anticoagulation Use: Case Studies in Anticoagulation Stewardship. Anticoagulant use is essential but carries significant risks if not managed properly. This article dives into four patient case studies, addressing challenges like: 🩸Inappropriate dosing of DOACs 🩸Diagnosis and management of heparin-induced thrombocytopenia (HIT) 🩸Periprocedural anticoagulation management 🩸Heavy menstrual bleeding while on anticoagulation Each case study underscores how anticoagulation stewardship programs can close care gaps, ensure safe practices, and improve patient outcomes. We extend our congratulations and gratitude to these incredible authors, including AC Forum leaders, for their dedication to advancing patient care and safety: Jori May, Arthur Allen, Bethany Samuelson Bannow, Carlee O’Connor, Katelyn Sylvester, PharmD, BCPS, CACP, and Scott Kaatz. 👉 Read the full article in JTH here: https://bit.ly/3Br4DPC Share with your colleagues and network to spread this impactful work!

We are pleased to share an article on "The value of accessible vascular assessment tools in diabetic foot disease: An audit of a tertiary level hospital" that was published in the Medical Independent. Authored by Astrid Codemo, this article explores the clinical impact of the BlueDop device in improving vascular assessments for patients with diabetic foot disease. Click here to read in full: https://lnkd.in/giGDqmFj The audit highlights the potential of accessible technologies like BlueDop to transform vascular health. Key findings include: - The BlueDop device, developed in 2010, enables a cuff-free measurement of the Ankle-Brachial Pressure Index (ABPI) by assessing arterial blood flow in the posterior tibial or dorsalis pedis artery. - In an audit of 23 diabetic patients with active foot ulceration, BlueDop assessments reduced waiting times to just 11 working days, compared with over 10 weeks for traditional vascular laboratory assessments. - The device demonstrated its ability to provide reliable readings even in cases of non-compressible vessels, addressing a key limitation of traditional ABPI methods. With its accessibility and efficiency, BlueDop is particularly suited to community healthcare settings, helping to bridge gaps in care and improve access to timely assessments. The findings underscore the importance of innovative diagnostic tools in reducing delays and improving outcomes for patients with diabetic foot disease. BlueDop is proud to play a part in setting new standards for vascular health. We would like to thank Astrid for her rigorous work in showcasing the clinical potential of the BlueDop device and for furthering the conversation around improving vascular care. Astrid’s efforts align with our mission to make vascular diagnostics more accessible, accurate, and patient-centred. At BlueDop, we remain committed to advancing vascular diagnostics, empowering healthcare providers, and improving patient outcomes worldwide. If you are interested in learning more about this study or how BlueDop is helping to shape the future of vascular health find out more at www.BlueDop.com #HealthcareInnovation #VascularHealth #DiabetesCare #MedicalResearch #PatientCentredCare